SITE011-0049

SITE011 (ITA) › SITE011-0049

SITE011-0049

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2025-11-05

enrolled

AEs

6

Serious

0

Dropout signal

–

Adverse events

6

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-11 (study day 309); relationship: not assessed

mild assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-01-13 (study day 252); relationship: RELATED

moderate assessed

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 235); relationship: not assessed

moderate assessed

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-07-03 (study day 58); relationship: NOT RELATED

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-05-30 (study day 24); relationship: NOT RELATED

moderate assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-11 (study day 5); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.